JP7702654B2 - トリプタミンプロドラッグ - Google Patents

トリプタミンプロドラッグ Download PDF

Info

Publication number
JP7702654B2
JP7702654B2 JP2022580938A JP2022580938A JP7702654B2 JP 7702654 B2 JP7702654 B2 JP 7702654B2 JP 2022580938 A JP2022580938 A JP 2022580938A JP 2022580938 A JP2022580938 A JP 2022580938A JP 7702654 B2 JP7702654 B2 JP 7702654B2
Authority
JP
Japan
Prior art keywords
alkyl
compounds
compound
depression
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022580938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531311A5 (https=
JPWO2022000091A5 (https=
JP2023531311A (ja
Inventor
ブライソン、ネイサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reunion Neuroscience Inc
Original Assignee
Reunion Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reunion Neuroscience Inc filed Critical Reunion Neuroscience Inc
Publication of JP2023531311A publication Critical patent/JP2023531311A/ja
Publication of JP2023531311A5 publication Critical patent/JP2023531311A5/ja
Publication of JPWO2022000091A5 publication Critical patent/JPWO2022000091A5/ja
Priority to JP2025094025A priority Critical patent/JP2025143280A/ja
Application granted granted Critical
Publication of JP7702654B2 publication Critical patent/JP7702654B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022580938A 2020-06-30 2021-06-30 トリプタミンプロドラッグ Active JP7702654B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025094025A JP2025143280A (ja) 2020-06-30 2025-06-05 トリプタミンプロドラッグ

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063045901P 2020-06-30 2020-06-30
US63/045,901 2020-06-30
US202063109095P 2020-11-03 2020-11-03
US63/109,095 2020-11-03
US17/364,047 US11292765B2 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs
US17/364,047 2021-06-30
PCT/CA2021/050907 WO2022000091A1 (en) 2020-06-30 2021-06-30 Tryptamine prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025094025A Division JP2025143280A (ja) 2020-06-30 2025-06-05 トリプタミンプロドラッグ

Publications (4)

Publication Number Publication Date
JP2023531311A JP2023531311A (ja) 2023-07-21
JP2023531311A5 JP2023531311A5 (https=) 2024-07-09
JPWO2022000091A5 JPWO2022000091A5 (https=) 2024-07-09
JP7702654B2 true JP7702654B2 (ja) 2025-07-04

Family

ID=79032374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580938A Active JP7702654B2 (ja) 2020-06-30 2021-06-30 トリプタミンプロドラッグ
JP2025094025A Pending JP2025143280A (ja) 2020-06-30 2025-06-05 トリプタミンプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025094025A Pending JP2025143280A (ja) 2020-06-30 2025-06-05 トリプタミンプロドラッグ

Country Status (10)

Country Link
US (4) US11292765B2 (https=)
EP (1) EP4172145A4 (https=)
JP (2) JP7702654B2 (https=)
KR (2) KR20250103811A (https=)
CN (3) CN115867533B (https=)
AU (1) AU2021302692A1 (https=)
CA (1) CA3181092A1 (https=)
IL (2) IL299506B2 (https=)
MX (1) MX2022016212A (https=)
WO (1) WO2022000091A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
MX2022009528A (es) 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
CN115867533B (zh) * 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
WO2022040802A1 (en) * 2020-08-26 2022-03-03 Magicmed Industries Inc. Glycosylated psilocybin derivatives and methods of using
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
EP4263504A4 (en) * 2020-12-18 2025-05-14 COMPASS Pathfinder Limited Modified indole alkaloids for therapeutic uses
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
BR112023025599A2 (pt) 2021-06-08 2024-02-20 Entheogenix Biosciences Inc Ativadores de dimetoxifenilalquilamina de receptores de serotonina.
CA3225133A1 (en) 2021-07-07 2023-01-12 Matthew Alexander James Duncton N,n-dimethyltryptamine and related psychedlics and uses thereof
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
WO2023023347A1 (en) * 2021-08-20 2023-02-23 Terran Biosciences Inc. Prodrugs and derivatives of psilocin and uses thereof
EP4429672A4 (en) 2021-11-12 2025-04-30 Terran Biosciences Inc. PSILOCYBIN AND O-ACETYLPSILOCIN, SALTS AND SOLID FORMS THEREOF
US12404238B2 (en) 2021-12-10 2025-09-02 Caamtech, Inc. Psilocybin derivatives
JP2024546138A (ja) * 2021-12-14 2024-12-17 レユニオン ニューロサイエンス，インコーポレイテッド トリプタミンプロドラッグ
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023133477A1 (en) * 2022-01-06 2023-07-13 Terran Biosciences, Inc. Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20250186369A1 (en) * 2022-03-07 2025-06-12 Drexel University Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493542A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc C4-CARBONOTHIOATE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USE
AU2022446955A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
EP4493544A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE
WO2023201293A2 (en) * 2022-04-13 2023-10-19 Caamtech, Inc. Tryptamine derivatives
CN115521240B (zh) * 2022-06-01 2024-05-28 杭州奥泰生物技术股份有限公司 一种二甲基色胺半抗原和人工抗原及其制备方法与应用
EP4561527A2 (en) * 2022-07-27 2025-06-04 Reconnect Labs AG Highly soluble formulations of harmine
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
CN116283885B (zh) * 2022-12-01 2025-02-14 杭州奥泰生物技术股份有限公司 一种帕罗西汀半抗原和人工抗原及其制备方法与应用
JP2026501775A (ja) * 2023-01-05 2026-01-16 リユニオン・ニューロサイエンス、インコーポレイテッド トリプタミンプロドラッグの薬物動態の改善
WO2024178051A2 (en) * 2023-02-22 2024-08-29 Caamtech, Inc. Tryptamine derivatives
EP4704822A1 (en) 2023-05-01 2026-03-11 ATAI Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2025099725A1 (en) * 2023-11-09 2025-05-15 Hadasit Medical Research Services And Development Ltd. Conjugates and uses thereof
WO2025238416A1 (en) * 2024-05-16 2025-11-20 Mindset Pharma Inc. Indole derivatives, uses and compositions thereof
WO2025250900A1 (en) * 2024-05-30 2025-12-04 Caamtech, Inc. 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate
WO2026024591A1 (en) * 2024-07-22 2026-01-29 Reunion Neuroscience, Inc. Tryptamine prodrug solid forms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075992A (en) 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
WO1995006638A1 (en) 1993-09-01 1995-03-09 Allelix Biopharmaceuticals Inc. Tryptamine analogs with 5-ht1d selectivity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL243249A (https=) 1958-09-12
CH373381A (de) 1959-07-13 1963-11-30 Sandoz Ag Verfahren zur Herstellung neuer basischer Indol-Derivate
CH386422A (de) 1960-03-30 1965-01-15 Sandoz Ag Verfahren zur Herstellung neuer Ester der Indol-Reihe
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AU2005300045A1 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
PL2352497T3 (pl) 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
EP4219498A1 (en) * 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
CN115867533B (zh) * 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
EP4263504A4 (en) * 2020-12-18 2025-05-14 COMPASS Pathfinder Limited Modified indole alkaloids for therapeutic uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075992A (en) 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
WO1995006638A1 (en) 1993-09-01 1995-03-09 Allelix Biopharmaceuticals Inc. Tryptamine analogs with 5-ht1d selectivity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
F． Hasler et al.，Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokineti，PHARMACEUTICA ACTA HELVETIAE，1997年，72，175-184
Howard Sard et al.，SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist，BIOORGANIC & MEDICINAL CHEMISTRY LETTERS，15，2005年，4555-4559
Martin K. Madsen et al.，Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin，Neuropsychopharmacology，44，2019年，1328-1334

Also Published As

Publication number Publication date
CA3181092A1 (en) 2022-01-06
US20210403425A1 (en) 2021-12-30
WO2022000091A1 (en) 2022-01-06
MX2022016212A (es) 2023-03-02
CN119285526A (zh) 2025-01-10
EP4172145A4 (en) 2024-08-21
CN115867533A (zh) 2023-03-28
JP2025143280A (ja) 2025-10-01
IL299506A (en) 2023-02-01
IL299506B1 (en) 2025-06-01
CN115867533B (zh) 2024-07-23
KR20250103811A (ko) 2025-07-07
IL299506B2 (en) 2025-10-01
EP4172145A1 (en) 2023-05-03
KR102829078B1 (ko) 2025-07-04
US20220177427A1 (en) 2022-06-09
US11292765B2 (en) 2022-04-05
AU2021302692A1 (en) 2023-01-19
IL320601A (en) 2025-07-01
US20250129023A1 (en) 2025-04-24
US20250382267A1 (en) 2025-12-18
KR20230028543A (ko) 2023-02-28
CN119285527A (zh) 2025-01-10
JP2023531311A (ja) 2023-07-21

Similar Documents

Publication Publication Date Title
JP7702654B2 (ja) トリプタミンプロドラッグ
US20250051278A1 (en) Tryptamine prodrugs
JP2024514703A (ja) ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用
EA007008B1 (ru) Триамидзамещённые индолы, бензофураны и бензотиофены в качестве ингибиторов микросомального белка, переносящего триглицериды, (мтр) и/или ингибиторов секреции аполипопротеина в (аро в)
CN106146337A (zh) 用于治疗ape1介导的疾病的醌化合物
JPH04244024A (ja) 痴呆及び脳血管障害予防・治療剤並びに血小板凝集抑制剤
JP2018537526A (ja) ボルテゾミブ複合体及びその使用方法
CA3075324A1 (en) Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof
JPWO2014129513A1 (ja) 潰瘍性大腸炎の予防または治療剤と新規フラーレン誘導体
JP7512251B2 (ja) 病的炎症の新しい医療
JP2021512958A (ja) 神経変性疾患を治療するための医薬及びその使用
HK40114252A (zh) 色胺前药
HK40114605A (zh) 色胺前药
HK40114112A (zh) 色胺前药
HK40091294A (zh) 色胺前药
HK40091294B (zh) 色胺前药
CN108558869B (zh) 用于治疗肝癌的化合物及其制剂
WO2025099725A1 (en) Conjugates and uses thereof
JP2024516114A (ja) メラトニン受容体の新規調節因子、ならびにその製造方法および使用
CN115103850A (zh) 2-甲氧基雌二醇衍生物及其医学用途
WO2021172488A1 (ja) 環状アミン誘導体及びその医薬用途
JPWO2016084870A1 (ja) アシルアミノフェニル基を有する化合物及びその用途

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20250530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250530

R150 Certificate of patent or registration of utility model

Ref document number: 7702654

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02